MX2021000779A - Nuevas particulas portadoras para formulaciones de polvo seco para inhalacion. - Google Patents

Nuevas particulas portadoras para formulaciones de polvo seco para inhalacion.

Info

Publication number
MX2021000779A
MX2021000779A MX2021000779A MX2021000779A MX2021000779A MX 2021000779 A MX2021000779 A MX 2021000779A MX 2021000779 A MX2021000779 A MX 2021000779A MX 2021000779 A MX2021000779 A MX 2021000779A MX 2021000779 A MX2021000779 A MX 2021000779A
Authority
MX
Mexico
Prior art keywords
inhalation
dry powder
carrier particles
powder formulations
novel carrier
Prior art date
Application number
MX2021000779A
Other languages
English (en)
Inventor
Tomaso Guidi
Amrit Paudel
Sarah Elisabeth Zellnitz
Pinto Joana Filipa Fernandes Teixeira
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2021000779A publication Critical patent/MX2021000779A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a partículas portadoras adecuadas para su uso en formulaciones de polvo seco para inhalación. La invención también se refiere a procesos para su preparación mediante congelación por pulverización.
MX2021000779A 2018-07-27 2019-07-24 Nuevas particulas portadoras para formulaciones de polvo seco para inhalacion. MX2021000779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18186078 2018-07-27
PCT/EP2019/069943 WO2020020957A1 (en) 2018-07-27 2019-07-24 Novel carrier particles for dry powder formulations for inhalation

Publications (1)

Publication Number Publication Date
MX2021000779A true MX2021000779A (es) 2021-03-31

Family

ID=63079833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000779A MX2021000779A (es) 2018-07-27 2019-07-24 Nuevas particulas portadoras para formulaciones de polvo seco para inhalacion.

Country Status (11)

Country Link
US (1) US11813360B2 (es)
EP (1) EP3829641B1 (es)
JP (1) JP7439084B2 (es)
KR (1) KR20210040102A (es)
CN (1) CN112469443B (es)
AU (1) AU2019311268A1 (es)
BR (1) BR112021001402A2 (es)
CA (1) CA3105265A1 (es)
MA (1) MA53324A (es)
MX (1) MX2021000779A (es)
WO (1) WO2020020957A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US20030188679A1 (en) * 2000-08-25 2003-10-09 Eugen Schwarz Powdered mannitol and mannitol-containing compositions
JP4062436B2 (ja) * 2000-11-06 2008-03-19 旭化成ケミカルズ株式会社 セルロース系製剤用粒子
WO2002098348A2 (en) * 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
EP1386630B1 (en) 2002-07-31 2006-05-17 CHIESI FARMACEUTICI S.p.A. Powder inhaler
US20070065372A1 (en) 2003-02-21 2007-03-22 Robert Price Process for the production of particles
US20080199527A1 (en) * 2004-12-21 2008-08-21 Pfizer Inc. Enteric Coated Azithromycin Multiparticulates
GB0705159D0 (en) 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
GB0711680D0 (en) 2007-06-18 2007-07-25 Prosonix Ltd Process
PL2273983T3 (pl) 2008-05-09 2017-01-31 Grünenthal GmbH Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
JP5947543B2 (ja) 2008-07-18 2016-07-06 プロソニックス リミテッドProsonix Limited 結晶化度を改善する方法
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2011069197A1 (en) 2009-12-08 2011-06-16 The University Of Sydney Inhalable formulations
EP2601973A1 (en) 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic

Also Published As

Publication number Publication date
CN112469443A (zh) 2021-03-09
EP3829641B1 (en) 2024-05-22
CN112469443B (zh) 2024-04-16
MA53324A (fr) 2021-06-09
EP3829641A1 (en) 2021-06-09
US11813360B2 (en) 2023-11-14
AU2019311268A1 (en) 2021-02-11
CA3105265A1 (en) 2020-01-30
KR20210040102A (ko) 2021-04-12
JP7439084B2 (ja) 2024-02-27
JP2021531948A (ja) 2021-11-25
WO2020020957A1 (en) 2020-01-30
BR112021001402A2 (pt) 2021-04-27
US20210290540A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX336414B (es) Proceso de preparacion de particulas portadoras para polvos secos para inhalacion.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2012012045A (es) Proceso para proporcionar particulas con cargas electrostaticas reducidas.
PH12018500852B1 (en) Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use
JO3154B1 (ar) عوامل مضادة لـ trpv4
MX2020009416A (es) Nuevos reactivos a base de fosforo (v), procesos para su preparacion y su uso en la elaboracion de compuestos de organofosforo (v) estereo-definidos.
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
IN2015DN03336A (es)
MX2020005478A (es) Compuestos de sulfonamida y usos de los mismos.
MX2018000743A (es) Granulos de manitol para compresion directa.
MX2015013254A (es) Composiciones de agente activo retinoide particuladas, secas y finas y formulaciones topicas que incluyen las mismas.
TN2017000018A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases.
GB2514741A (en) Composition for use as a paint binder
IN2013MU01177A (es)
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
MX2021000779A (es) Nuevas particulas portadoras para formulaciones de polvo seco para inhalacion.
PH12018502139A1 (en) Phosphaplatin liquid formulations
EP3600366A4 (en) PROCESS FOR THE PREPARATION OF PROBIOTIC POWDER FORMULATIONS FOR MONOGASTRIC ANIMALS
IN2014DN10135A (es)
MX2019013570A (es) Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.
MX2016002714A (es) Composicion y metodo para tropicalizar chocolate.
GEP20196944B (en) Process for preparing the inhalation formulations
MX2022003427A (es) Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.